Prevention and treatment of thrombosis in cancer and oncohematological patients

Сомонова, О В; Елизарова, А. Л.

doi:10.17650/1818-8346-2021-16-4-40-49

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncological disease is known to increase the risk of deep vein thrombosis and pulmonary embolism by 4–7 fold. One treatment option for hypercoagulation and venous thromboembolism is heparin (low-molecular-weight heparins)–one of the most widely used intravenous anticoagulants, exhibiting a unique polyanionic structure [ 54 , 55 ]. However, extensive heparin treatment is limited due to its hemorrhagic effect and the risk of heparin-induced thrombocytopenia [ 56 ].…”

Section: Anticoagulant and Antithrombotic Activitiesmentioning

confidence: 99%

Perspectives for the Use of Fucoidans in Clinical Oncology

Kiselevskiy

Anisimova

Ustyuzhanina

et al. 2022

IJMS

View full text Add to dashboard Cite

Fucoidans are natural sulfated polysaccharides that have a wide range of biological functions and are regarded as promising antitumor agents. The activity of various fucoidans and their derivatives has been demonstrated in vitro on tumor cells of different histogenesis and in experiments on mice with grafted tumors. However, these experimental models showed low levels of antitumor activity and clinical trials did not prove that this class of compounds could serve as antitumor drugs. Nevertheless, the anti-inflammatory, antiangiogenic, immunostimulating, and anticoagulant properties of fucoidans, as well as their ability to stimulate hematopoiesis during cytostatic-based antitumor therapy, suggest that effective fucoidan-based drugs could be designed for the supportive care and symptomatic therapy of cancer patients. The use of fucoidans in cancer patients after chemotherapy and radiation therapy might promote the rapid improvement of hematopoiesis, while their anti-inflammatory, immunomodulatory, and anticoagulant effects have the potential to improve the quality of life of patients with advanced cancer.

show abstract

Section: Anticoagulant and Antithrombotic Activitiesmentioning

confidence: 99%

Perspectives for the Use of Fucoidans in Clinical Oncology

Kiselevskiy

Anisimova

Ustyuzhanina

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Perioperative hemorheological status of oncological patients with primary knee replacement

Grushina,

Alexandrova,

Teplyakov

2023

jour

View full text Add to dashboard Cite

Introduction. Endoprosthesis of large joints is associated with high risk of venous thromboembolism. Researchers focus on biochemical characteristics of homeostasis, blood clotting in particular, as the main reason for abnormal blood flow. At the same time, biophysical condition of homeostasis, namely decreased blood fluidity, is rarely considered. Study of rheological behavior of blood after primary oncological endoprosthesis of large joints in patients can potentially affect the selection of perioperative thromboprophylaxis and patient rehabilitation approach.Aim. To study the indicators of the hemorheological status of patients with tumours of long bones in the preand postoperative periods of primary oncological knee replacement.Materials and methods. The study included 36 patients (26 men and 10 women, mean age 46 years) without cardiovascular diseases and pathology of the veins of the lower limb admitted to the Russian Scientific Center of Roentgen Radiology for oncological endoprosthesis of the knee joint. All patients were prescribed: an antiplatelet agent (acetylsalicylic acid) and an anticoagulant (enoxaparin sodium 40 mg daily). Distal resection of the femur (on average 14 cm) was performed in 28 patients, and proximal resection of the tibia (on average 12 cm) in 8 patients, followed by knee replacement. Before the operation, on the 1st and 6th days after the operation, the hemorheological status and the state of the hemostasis system were evaluated in all patients. To determine the reference values, 24 healthy people were examined, comparable in gender and age. Statistical analysis using Statistica 10.0.Results. During the preoperative examination, integral assessment showed the differences in the severity of hemorheological disorders between patients, and two groups were identified: Group 1 – 21 (61 %) patients whose hemorheological disorders were classified as severity degree I, and Group 2 – 14 (39 %) patients with severity degree II d. On day 1 after the surgery, both patient groups showed negative dynamics: hemorheological disorders in group 1 worsened from grade I to II d., and in group 2 to III d. (critical) (p <0.05). On day 6, the parameters did not change significantly in all patients. Similar dynamic changes were observed in the haemostasis system.Conclusion. Activation of the blood coagulation system and deterioration of hemorheology occurred after surgery during administration of anticoagulant and antiplatelet therapy. None of the patients had venous thromboembolic complications, however the risk of their development remained high. A differential model describing hemorheological status can be useful for selection of thromboprophylaxis and rehabilitation methods which include physical factors that improve the hemorheological profile: low-frequency magnetic and/or laser therapy in patients.

show abstract

Prevention and treatment of thrombosis in cancer and oncohematological patients

Cited by 2 publications

References 46 publications

Perspectives for the Use of Fucoidans in Clinical Oncology

Perspectives for the Use of Fucoidans in Clinical Oncology

Perioperative hemorheological status of oncological patients with primary knee replacement

Contact Info

Product

Resources

About